Pretargeted radioimmunotherapy: Clinically more efficient than conventional radioimmunotherapy?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 9, 2013, Pages 1373-1376

  Rousseau, Caroline ^a   Kraeber Bodéré, Françoise ^a,b   Barbet, Jacques ^c,d   Chatal, Jean François ^d  

^a UMR INSERM U892 CNRS 6299   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Team 12   (France)

^d Groupement d'Intérêt Public Arronax ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; RADIOISOTOPE;

COLORECTAL CARCINOMA; HUMAN; METASTATIC COLORECTAL CANCER; NONHUMAN; NOTE; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA; TOXICITY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, BISPECIFIC; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS;

EID: 84881660664     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2469-9     Document Type: Note

References (20)

1. Press OW, Palanca-Wessels MC. Selection of first-line therapy for advanced follicular lymphoma. J Clin Oncol. 2013;31:1496-9.
2. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005;23:6763-70.
3. van Rij CM, Lütje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging. 2013. doi: 10.1007/s00259-013-2434-7.
4. Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E, et al. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer. 1997;80:2618-23.
5. Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med. 2000;41:480-7.
6. Kraeber-Bodere F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, et al. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res. 1999;5:3183s-9s.
7. Kraeber-Bodere F, Faivre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, et al. Comparative toxicity and efficacy of one- and two-step (bispecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer. J Nucl Med. 1999;40:198-204.
8. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A. 2006;103:6841-6.
9. Schoffelen R, van der Graaf WTA, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51:1780-7.
10. Frampas E, Maurel C, Remaud-Le Saëc P, Mauxion T, Faivre-Chauvet A, Davodeau F, et al. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging. 2011;38:2153-64.
11. Kraeber-Bodéré F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5:3190s-8s.
12. Salaun PY, Campion L, Bournaud C, Faivre-Chauvet A, Vuillez JP, Taieb D, et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med. 2012;53:1185-92.
13. Juweid ME, Hajjar G, Swayne LC, Sharkey RM, Suleiman S, Herkovic T, et al. Phase I/II trial of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer. 1999;85:1828-42.
14. Mirallié E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-88.
15. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-11.
16. Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002;2:31-42.
17. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247-55.
18. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Béhé M, Markus PM, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002;94:1373-81.
19. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884-92.
20. Schoffelen R, van der Graaf WT, Sharkey RM, Franssen GM, McBride WJ, Chang CH, et al. Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Res. 2012;2:5.